Pisgah Labs’ PSE Extraction-Resistance Work Undeterred By Claims Outlook
This article was originally published in The Tan Sheet
Pisgah Labs patented a version of its P2P Interventions technology for pseudoephedrine extraction. But Pisgah and its competitors face a major challenge without an extraction-resistant claim approved by FDA.
You may also be interested in...
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee recommends against approval of Zogenix’s Zohydro ER as it seeks safer formulations and stricter REMS for all extended-release/long-acting opioids.
The spread of “one-pot” meth manufacturing will not deter Acura Pharmaceuticals from launching its OTC extraction-resistant PSE product, Nexafed. Making PSE products available in an extraction-resistant delivery formulation could offer an alternative to moving all dosages of the ingredient to the Rx class.
Officials from Mississippi, Missouri, Oregon and South Carolina and the National Narcotics Officers Associations Coalition testifying before a House subcommittee call for moving all PSE products to prescription status.